Skip to main content

Perfetti Riccardo's Form 4 filing

Applied Therapeutics, Inc. (APLT) · filed Aug 11, 2021

Accession no.
0001209191-21-051009
Filed
Aug 11, 2021
Trade date
Aug 9-10, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $405.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Perfetti RiccardoCIK 0001775410Officer (Chief Medical Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 9, 2021Common StockMOption exerciseAcquired+15,000$1.44+$21,60015,000Direct
Aug 9, 2021Common StockSSaleDisposed−10,300$17.18F3−$176,9544,700Direct
Aug 9, 2021Common StockSSaleDisposed−4,700$17.85F4−$83,8950Direct
Aug 10, 2021Common StockMOption exerciseDisposed−8,873$1.44−$12,777.128,873Direct
Aug 10, 2021Common StockSSaleAcquired+8,273$15.85F5+$131,127.05600Direct
Aug 10, 2021Common StockSSaleDisposed−800$16.35F6−$13,0800Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 9, 2021Common StockMOption exerciseDisposed−15,000$0.00$0103,747Direct
Aug 10, 2021Common StockMOption exerciseDisposed−8,873$0.00$094,874Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

Weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7500 to $17.7400 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F4

Weighted average price. These shares were sold in multiple transactions at prices ranging from $17.7500 to $18.0500 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F5

Weighted average price. These shares were sold in multiple transactions at prices ranging from $15.2200 to $16.1700 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

F6

Weighted average price. These shares were sold in multiple transactions at prices ranging from $16.2500 to $16.6100 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)